Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement - Talaris Therapeutics (NASDAQ:TALS)
Merger to create Nasdaq-listed, late-stage clinical biotechnology company focused on developing Tourmaline's anti-IL-6 antibody (TOUR006) in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD)
Source: benzinga.com